Strand Life Sciences Strand Life Sciences Strand Life Sciences Strand Life Sciences Strand Life Sciences

In the News

Watch how Strand is transforming cancer care in India on Times Now

Partnerships

HCG and Strand announce new standard-of-care for cancer treatment in India

HCG partnered with Strand Life Sciences to integrate genomics as a ‘standard of care’ in cancer treatment and risk prediction across its hospital network in India and Africa. The genomic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations will help identify targeted therapies and treatment choices early in the course of cancer care.

Read more about the partnership:

Press release
Coverage in The Hindu Business Line

Strand at Mazumdar Shaw (SAMS) translational genomics lab

Strand Life Sciences, in partnership with the Mazumdar Shaw Medical Foundation, has set up one of India’s first translational genomics laboratories at the Mazumdar-Shaw Centre for Translational Research (MSCTR) in the Narayana Health City campus at Bangalore. The SAMS lab will focus on translational research to develop affordable genomics-based diagnostics in the areas on oncology and inherited genetic diseases.

Read more about the SAMS lab on Business Standard
Read tweet from Dr. Kiran Mazumdar-Shaw about SAMS lab

Testimonials

Dr. Mammen Chandy

Precision Medicine in Oncology

“The complexity of cancer genetic pathways and mutations, combined with increasing options for targeted therapy, necessitate a comprehensive assessment of tumor mutation profiles in patients with solid tumors. Using a single drug to treat all types of cancers or patients is rapidly being discontinued for targeted and tailor-made therapies. Precision medicine today has made it possible to derive more effective treatment strategies that are tailored to the genomic profile of each patient’s tumor. On the other hand, genetic testing has enabled us to identify individuals and families with high risk of hereditary cancer, and provide them with personalized surveillance and risk-reduction measures.”

“I am convinced about the benefits and utility of molecular diagnostics for delivering effective cancer care, provided we are able to reach a point where the majority of the population can afford such important advances in medicine.”

Dr. Mammen Chandy, Director – Tata Medical Centre, Kolkata quotes at a symposium on ‘Next-Generation Sequencing for Precision Medicine in Oncology’ organized by Strand Life Sciences.

Dr. Senthil Rajappa

Precision Medicine in Oncology

“Precision medicine based on genomic profiling is expected to help tailor the treatment to the patient and the tumor. Genetic testing has enabled us to identify individuals and families with high risk of hereditary cancer, and provide them with personalized surveillance and risk-reduction measures. The opportunities and utility of precision medicine diagnostics for delivering effective cancer care is immense.

“I am convinced about the benefits and utility of molecular diagnostics for delivering effective cancer care, provided we are able to reach a point where the majority of the population can afford such important advances in medicine.”

Dr. Senthil Rajappa – Senior Consultant in Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad quotes at a symposium on ‘Next-Generation Sequencing for Precision Medicine in Oncology’ organized by Strand Life Sciences.

Adam Bass

Testimonial on Strand

“Strand Life Sciences has been a leader in genomic analysis for years. It is wonderful to see them bring their expertise into Personalized Medicine, where they can help physicians to effectively tailor therapies to the genomic profiles of their patients and their tumors.”

Adam Bass, MD
Assistant Professor, Harvard Medical School
Physician/Scientist – Dana-Farber Cancer Institute